.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,198,882

« Back to Dashboard

Claims for Patent: 9,198,882

Title:Enterically coated cysteamine, cystamine and derivatives thereof
Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Inventor(s): Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:14/752,383
Patent Claims: 1. A method of administering cysteamine or a pharmaceutically acceptable salt thereof to a patient with cystinosis, comprising administering to said patient a pharmaceutical composition comprising cysteamine or a pharmaceutically acceptable salt thereof, wherein the composition increases delivery of cysteamine or the pharmaceutically acceptable salt thereof to the small intestine, and wherein the frequency of administering is less than four times daily.

2. The method of claim 1, wherein each dose of cysteamine is about 0.5-1.0 g/m.sup.2 body surface area.

3. The method of claim 1, wherein the total daily dose of cysteamine is about 1.35 g/m.sup.2 body surface area or less.

4. The method of claim 1, wherein the cysteamine or salt thereof is cysteamine bitartrate.

5. The method of claim 1, wherein the composition comprises enterically coated cysteamine or the salt thereof.

6. The method of claim 5, wherein each dose of cysteamine is about 0.5-1.0 g/m.sup.2 body surface area.

7. The method of claim 5, wherein the total daily dose of cysteamine is about 1.35 g/m.sup.2 body surface area or less.

8. The method of claim 5, wherein the cysteamine or salt thereof is cysteamine bitartrate.

9. The method of claim 5, wherein the composition comprises a coating selected from the group consisting of polymerized gelatin, shellac, methacrylic acid copolymer type CNF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers formed from methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters.

10. A method of administering cysteamine or a pharmaceutically acceptable salt thereof to a patient with cystinosis, comprising administering to said patient a pharmaceutical composition comprising cysteamine or a pharmaceutically acceptable salt thereof, twice per day, wherein the composition increases delivery of cysteamine or the pharmaceutically acceptable salt thereof to the small intestine.

11. The method of claim 10, wherein each dose of cysteamine is about 0.5-1.0 g/m.sup.2 body surface area.

12. The method of claim 10, wherein the total daily dose of cysteamine is about 1.35 g/m.sup.2 body surface area or less.

13. The method of claim 10, wherein the cysteamine or salt thereof is cysteamine bitartrate.

14. The method of claim 10, wherein the composition comprises enterically coated cysteamine or the salt thereof.

15. The method of claim 14, wherein each dose of cysteamine is about 0.5-1.0 g/m.sup.2 body surface area.

16. The method of claim 14, wherein the total daily dose of cysteamine is about 1.35 g/m.sup.2 body surface area or less.

17. The method of claim 14, wherein the cysteamine or salt thereof is cysteamine bitartrate.

18. The method of claim 14, wherein the composition comprises a coating selected from the group consisting of polymerized gelatin, shellac, methacrylic acid copolymer type CNF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers formed from methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc